Novavax Inc. stock underperforms Wednesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Wednesday when compared to competitors | news.google.com • |
Novavax, Inc. (NASDAQ:NVAX) is Shah Capital Management's 2nd Largest Position | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | 1.82 | 0.99 | -0.83 | -45.60% |
2024-05-10 | 2024-03 | -1.04 | -1.05 | -0.01 | -0.96% |
2024-02-28 | 2023-12 | -0.49 | -1.44 | -0.95 | -193.88% |
2023-11-09 | 2023-09 | -1.82 | -1.26 | 0.56 | 30.77% |
2023-08-08 | 2023-06 | -1.24 | 0.58 | 1.82 | 146.77% |
2023-05-09 | 2023-03 | -3.38 | -3.41 | -0.03 | -0.89% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-08 | B. Riley Securities | Upgrade | Neutral | Buy |
2023-05-09 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-28 | B. Riley Securities | Downgrade | Buy | Neutral |
2023-02-12 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-01 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-06-11 | ALTON GREGG H | Director | 10.47K | Conversion of Exercise of derivative security |
2024-06-11 | DOUGLAS RICHARD H | Director | 43.92K | Conversion of Exercise of derivative security |
2024-06-16 | DUBOVSKY FILIP | Officer | 66.61K | Sale |
2024-08-15 | KELLY JAMES PATRICK | Chief Financial Officer | 14.43K | Conversion of Exercise of derivative security |
2024-06-11 | KING RACHEL K | Director | 18.92K | Conversion of Exercise of derivative security |
2024-06-11 | MCGLYNN MARGARET G | Director | 10.47K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | State Street Corporation | 11.68M | 86.78M | 12.37% |
2023-06-29 | Vanguard Group Inc | 10.57M | 78.55M | 11.20% |
2023-06-29 | Blackrock Inc. | 6.99M | 51.97M | 7.41% |
2023-09-29 | Shah Capital Management | 6.33M | 45.83M | 6.71% |
2023-06-29 | Bank of America Corporation | 2.18M | 16.23M | 2.31% |
2023-06-29 | Morgan Stanley | 2.08M | 15.46M | 2.20% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 9.38M | 75.07M | 9.94% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.64M | 19.60M | 2.79% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.23M | 16.56M | 2.36% |
2023-08-30 | iShares Russell 2000 ETF | 2.01M | 16.10M | 2.13% |
2023-06-29 | Vanguard Small-Cap Growth Index Fund | 1.28M | 9.48M | 1.35% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.21M | 8.98M | 1.28% |
Split | Date |
---|---|
1 : 20 | 2019-05-10 |
-
Novavax NVAX can be another potential winner in the COVID-19 vaccine race. Although the company’s COVID-19 vaccine is yet to receive an authorization/approval, the vaccine demonstrated robust efficacy in a late-stage study. In June 2021, Novavax announced data from the phase III PREVENT-19 study, which evaluated NVX-CoV2373 in the United States and Mexico. The study met its primary endpoint by demonstrating an overall vaccine efficacy of 90.4%. The vaccine also provided 100% protection against moderate and severe disease — a key secondary endpoint. The company plans to file for emergency use authorization with the FDA in the fourth quarter of 2021. The company is also developing a booster dose of its COVID-19 vaccine.
-
-
-
-
-
-
-
-
$NVAX pump and Friday dump
-
$NVAX be careful, bear trap
-
Help Reddit!
-
$NVAX waiting under 200$ for re enter
-
Learn to pull the trigger people. This stock fluctuates crazy. Sell high and buy back every couple days when it drops
-
Remember that 3 days ago we were at $179
-
There is the 20% drop. Now you can start buying for a quick bounce. Remember that next week, we most likely see the $165
-
-
-
3 days ago we were at $180, so we might see it again today. But $188-190 will be a nice entry for a quick bounce
-
By the way, my predictions are based on money movements and sentiments of the investors. I do believe NVAX will eventually go back to its ATH as soon they start getting orders and approvals. So if the price goes down to $165 next week. That will be a good entry point.
-
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
(NVAX) Trading Report
news.google.com • -
Novavax Inc. stock outperforms competitors on strong trading day
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Novavax Inc. stock underperforms Thursday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Thursday when compared to competitors
news.google.com • -
Why Are Novavax Shares Trading Lower Today?
news.google.com • -
Novavax, Inc. (NVAX) Baird 2024 Global Healthcare Conference (Transcript)
seekingalpha.com • -
Novavax to Participate in Upcoming September Conferences
prnewswire.com • -
Novavax: Staying Long Despite Coming Up Short In Q2
seekingalpha.com • -
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
marketbeat.com • -
Novavax, Inc. (NVAX) Q2 2024 Earnings Call Transcript
seekingalpha.com •